INTENDED AUDIENCE

• Drug manufacturers, packers, or distributors that promote their prescription drugs (NDAs, BLAs, and ANDAs) to consumers, patients, and caregivers
• Advertising firms that create prescription drug advertisements
• Regulatory affairs professionals working on prescription drug promotion
• Regulatory affairs professionals who submit prescription drug promotional communications to FDA
• General public wanting a better understanding of prescription drug advertising and promotion

The webinar will provide background information on prescription drug promotion, including different categories and types of promotion, as well as regulatory requirements for each. Interested parties will then learn about the CCN final rule, including the five standards associated with the rule and the rule’s compliance date. Finally, the speaker will note available FDA resources to assist firms in complying with the CCN final rule and applicable requirements for prescription drug promotion.

SPEAKER

Suzanna Boyle, JD
Regulatory Counsel
Division of Promotion Policy, Research and Operations (DPPRO)
Office of Prescription Drug Promotion (OPDP)
Office of Medical Policy (OMP) | CDER | FDA

The information presented can be used to gain a general understanding about prescription drug promotion and applicable requirements. In addition, participants will utilize the information to understand the effect the final rule has on DTC prescription drug advertising in TV or radio format. Attendees will be able to apply the information to help ensure the presentation of the major statement in their ads complies with the CCN rule.

Time: 1:00 PM – 2:00 PM ET

REGISTER

Browse through the extensive CDER SBIA Learn Online Training Repository, which contains guidance for all stages of pharmaceutical research, review, and manufacturing. You can also keep up with the latest announcements via CDER SBIA email updates.